{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:32:53Z","timestamp":1777084373893,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00520-011-1363-x","type":"journal-article","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T12:02:37Z","timestamp":1326715357000},"page":"2501-2509","source":"Crossref","is-referenced-by-count":12,"title":["Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care"],"prefix":"10.1007","volume":"20","author":[{"given":"Massimo","family":"Destro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Ottolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"issue":"1","key":"1363_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/ctrv.2000.0192","volume":"27","author":"S Mercadante","year":"2001","unstructured":"Mercadante S (2001) The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 27(1):51\u201361","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1363_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0885-3924(98)00081-5","volume":"16","author":"SK Joishy","year":"1998","unstructured":"Joishy SK, Walsh D (1998) The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J Pain Symptom Manage 16(5):334\u2013339","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"1363_CR3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0959-8049(02)00102-8","volume":"38","author":"S Mercadante","year":"2002","unstructured":"Mercadante S, Fulfaro F, Casuccio A (2002) A randomised controlled study on the use of anti-inflammatory drugs in patients whit cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 38(10):1358\u20131363","journal-title":"Eur J Cancer"},{"issue":"6","key":"1363_CR4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1097\/00000542-200506000-00027","volume":"102","author":"E Marret","year":"2005","unstructured":"Marret E, Kurdi O, Zufferey P et al (2005) Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects. Anesthesiology 102(6):1249\u20131260","journal-title":"Anesthesiology"},{"issue":"1","key":"1363_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00315271","volume":"44","author":"R Bj\u00f6rkman","year":"1993","unstructured":"Bj\u00f6rkman R, Ullman A, Hendner J (1993) Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 44(1):1\u20135","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1363_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0885-3924(97)00005-5","volume":"14","author":"S Mercadante","year":"1997","unstructured":"Mercadante S, Sapio M, Caligara M et al (1997) Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 14(1):15\u201320","journal-title":"J Pain Symptom Manage"},{"key":"1363_CR7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/1097-0142(19880715)62:2<407::AID-CNCR2820620227>3.0.CO;2-T","volume":"62","author":"E Bruera","year":"1998","unstructured":"Bruera E, Brenneis C, Michaud M et al (1998) Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 62:407\u2013411","journal-title":"Cancer"},{"key":"1363_CR8","volume-title":"Symptom management in advanced cancer","author":"R Twycross","year":"2001","unstructured":"Twycross R, Wilcock A (2001) Symptom management in advanced cancer, 3rd edn. Radcliffe Medical Press, Oxford","edition":"3"},{"key":"1363_CR9","volume-title":"The Syringe Driver: continuous subcutaneous infusions in palliative care","author":"A Dickman","year":"2005","unstructured":"Dickman A, Schneider J, Varga J (2005) The Syringe Driver: continuous subcutaneous infusions in palliative care, 2nd edn. University Press, Oxford","edition":"2"},{"issue":"823","key":"1363_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.70.823.359","volume":"70","author":"KG Myers","year":"1994","unstructured":"Myers KG, Trotman I (1994) Use of ketorolac by continuous subcutaneous infusion for the control of cancer pain. Postgrad Med J 70(823):359\u2013362","journal-title":"Postgrad Med J"},{"key":"1363_CR11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12968\/ijpn.2004.10.8.19532","volume":"10","author":"S Morgan","year":"2004","unstructured":"Morgan S, Evans N (2004) A small observational study of the longevity of syringe driver sites in palliative care. Int J Palliat Nurs 10:405\u2013412","journal-title":"Int J Palliat Nurs"},{"key":"1363_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.12968\/ijpn.2001.7.2.8918","volume":"7","author":"T Mitten","year":"2001","unstructured":"Mitten T (2001) Subcutaneous drug infusions: a review of problems and solutions. Int J Palliat Nurs 7:75\u201385","journal-title":"Int J Palliat Nurs"},{"issue":"4","key":"1363_CR13","first-page":"550","volume":"44","author":"F Toscani","year":"1994","unstructured":"Toscani F, Corli O, Speranza R et al (1994) Ketorolac versus diclofenac sodium in cancer pain. Arzneimittelforschung 44(4):550\u2013554","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"1363_CR14","first-page":"96","volume":"85","author":"F Panutti","year":"1999","unstructured":"Panutti F, Robustelli della Cuna G et al (1999) A double-blind evaluation of the analgesic afficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD\/10 recordati Protocol Study Group. Tumori 85(2):96\u2013100","journal-title":"Tumori"},{"issue":"3","key":"1363_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0952-8180(01)00382-8","volume":"14","author":"R Alexander","year":"2002","unstructured":"Alexander R, El-Moalem HE, Gan TJ (2002) Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopaedic surgery. J Clin Anesth 14(3):187\u2013192","journal-title":"J Clin Anesth"},{"issue":"2","key":"1363_CR16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpharm.2005.10.017","volume":"307","author":"S Negro","year":"2006","unstructured":"Negro S, Reyes R, Azuara ML et al (2006) Morphine, haloperidol and hyoscine N-butyl bromide combined in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients. Int J Pharm 307(2):278\u2013284","journal-title":"Int J Pharm"},{"issue":"1","key":"1363_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0378-5173(99)00181-7","volume":"187","author":"A Vermeire","year":"1999","unstructured":"Vermeire A, Remon JP (1999) Stability and compatibility of morphine. Int J Pharm 187(1):17\u201351, Review","journal-title":"Int J Pharm"},{"issue":"1","key":"1363_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(98)00324-X","volume":"177","author":"A Vermeire","year":"1999","unstructured":"Vermeire A, Remon JP (1999) Compatibility and stability of ternary admixtures of morphine with haloperidol or midazolam and dexamethasone or methylprednisolone. Int J Pharm 177(1):53\u201367","journal-title":"Int J Pharm"},{"key":"1363_CR19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.2042-7158.1996.tb05892.x","volume":"48","author":"J Fransson","year":"1996","unstructured":"Fransson J, Espander-Jansson A (1996) Local tolerance of subcutaneous injections. J Pharm Pharmacol 48:1012\u20131015","journal-title":"J Pharm Pharmacol"},{"key":"1363_CR20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2710.1988.tb00203.x","volume":"13","author":"M Olcer","year":"1988","unstructured":"Olcer M, Hakyemez G (1988) Investigations of some physicochemical properties of haloperidol which may effect its activity. J Clin Pharmacol Ther 13:341\u2013349","journal-title":"J Clin Pharmacol Ther"},{"key":"1363_CR21","first-page":"2963","volume":"51","author":"E Huang","year":"1994","unstructured":"Huang E, Anderson RP (1994) Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 51:2963","journal-title":"Am J Hosp Pharm"},{"key":"1363_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s005200100303","volume":"10","author":"S Negro","year":"2002","unstructured":"Negro S, Azuara ML, Sanchez Y et al (2002) Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 10:65\u201370","journal-title":"Support Care Cancer"},{"key":"1363_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-002-0415-7","volume":"11","author":"E Barcia","year":"2003","unstructured":"Barcia E, Reyes R, Luz Azuara M et al (2003) Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer in palliative care. Support Care Cancer 11:107\u2013113","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1363-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-011-1363-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-011-1363-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T21:49:07Z","timestamp":1593553747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-011-1363-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,16]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1007\/s00520-011-1363-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,16]]}}}